Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.69, $0.08 better than the analyst estimate of $0.61. Revenue for the quarter came in at $33.38 million versus the consensus estimate of $30.91 million.

GUIDANCE:

Ligand Pharma sees FY2017 revenue of $134-136 million, versus the consensus of $134.5 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.